{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:26Z","timestamp":1760298086511,"version":"3.37.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,5,22]],"date-time":"2009-05-22T00:00:00Z","timestamp":1242950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1038\/hr.2009.66","type":"journal-article","created":{"date-parts":[[2009,5,22]],"date-time":"2009-05-22T08:39:08Z","timestamp":1242981548000},"page":"625-630","source":"Crossref","is-referenced-by-count":22,"title":["Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation"],"prefix":"10.1038","volume":"32","author":[{"given":"Makoto","family":"Sugihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Takamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaaki","family":"Arimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinari","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keijiro","family":"Saku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,22]]},"reference":[{"key":"BFhr200966_CR1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","volume":"52","author":"M De Gasparo","year":"2000","unstructured":"De Gasparo M, Catt K, Inagami T, Wright JW, Unger T . International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415\u2013472.","journal-title":"Pharmacol Rev"},{"key":"BFhr200966_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1291\/hypres.26.937","volume":"26","author":"S Miura","year":"2003","unstructured":"Miura S, Saku K, Karnik SS . Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 2003; 26: 937\u2013943.","journal-title":"Hypertens Res"},{"key":"BFhr200966_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/hr.2008.2","volume":"32","author":"Japanese Society of Hypertension","year":"2009","unstructured":"Japanese Society of Hypertension. Committee for Guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 11\u201323.","journal-title":"Hypertens Res"},{"key":"BFhr200966_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11886-003-0105-1","volume":"5","author":"J Cruickshank","year":"2003","unstructured":"Cruickshank J . The J-curve in hypertension. Curr Cardiol Rep 2003; 5: 441\u2013452.","journal-title":"Curr Cardiol Rep"},{"key":"BFhr200966_CR5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","volume":"144","author":"FH Messerli","year":"2006","unstructured":"Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ . Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884\u2013893.","journal-title":"Ann Intern Med"},{"key":"BFhr200966_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1001\/archinte.163.3.361","volume":"163","author":"H Arima","year":"2003","unstructured":"Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, Tanaka K, Ohkubo K, Nakamura H, Abe I, Fujishima M, Iida M . Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med 2003; 163: 361\u2013366.","journal-title":"Arch Intern Med"},{"key":"BFhr200966_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/path.2314","volume":"215","author":"A Savchenko","year":"2008","unstructured":"Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, Emura I, Iwanari H, Sagara M, Tanaka T, Hamakubo T, Kodama T, Naito M . Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215: 48\u201355.","journal-title":"J Pathol"},{"key":"BFhr200966_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1161\/01.CIR.0000140265.21608.8E","volume":"110","author":"D Fliser","year":"2004","unstructured":"Fliser D, Buchholz K, Haller H, EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103\u20131107.","journal-title":"Circulation"},{"key":"BFhr200966_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/01.fjc.0000137160.76616.cc","volume":"44","author":"M Graninger","year":"2004","unstructured":"Graninger M, Reiter R, Drucker C, Minar E, Jilma B . Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004; 44: 335\u2013339.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFhr200966_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/01.CIR.101.3.305","volume":"101","author":"M Usui","year":"2000","unstructured":"Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, Takeya M, Yoshimura T, Matsushima K, Takeshita A . Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305\u2013310.","journal-title":"Circulation"},{"key":"BFhr200966_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.thromres.2005.04.008","volume":"117","author":"S Nomura","year":"2006","unstructured":"Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T . Effect of valsartan on monocyte\/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385\u2013392.","journal-title":"Thromb Res"},{"key":"BFhr200966_CR12","first-page":"93","volume":"13","author":"S Peters","year":"2001","unstructured":"Peters S, Gotting B, Trummel M, Rust H, Brattstrom A . Valsartan for prevention of restenosis after stenting of type B2\/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13: 93\u201397.","journal-title":"J Invasive Cardiol"},{"key":"BFhr200966_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00129784-200505010-00006","volume":"5","author":"DH Smith","year":"2005","unstructured":"Smith DH, Dubiel R, Jones M . Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41\u201350.","journal-title":"Am J Cardiovasc Drugs"},{"key":"BFhr200966_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10157-007-0463-x","volume":"11","author":"E Imai","year":"2007","unstructured":"Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S . Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007; 11: 156\u2013163.","journal-title":"Clin Exp Nephrol"},{"key":"BFhr200966_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00004872-200301000-00013","volume":"21","author":"JA Greenberg","year":"2003","unstructured":"Greenberg JA . Removing confounders from the relationship between mortality risk and systolic blood pressure at low and moderately increased systolic blood pressure. J Hypertens 2003; 21: 49\u201356.","journal-title":"J Hypertens"},{"key":"BFhr200966_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1527-3466.2006.00033.x","volume":"24","author":"K Prasado","year":"2006","unstructured":"Prasado K . C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 33\u201350.","journal-title":"Cardiovasc Drug Rev"},{"key":"BFhr200966_CR17","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.jacc.2003.12.051","volume":"43","author":"K Yasunari","year":"2004","unstructured":"Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A . Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 2116\u20132123.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr200966_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.clinthera.2005.05.006","volume":"27","author":"LM Ruilope","year":"2005","unstructured":"Ruilope LM, Malacco E, Khder Y, Kandra A, B\u00f6nner G, Heintz D . Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005; 27: 578\u2013587.","journal-title":"Clin Ther"},{"key":"BFhr200966_CR19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.atherosclerosis.2007.05.031","volume":"197","author":"N Kotooka","year":"2008","unstructured":"Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, Uchida T, Sugiyama A, Node K . Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 2008; 197: 368\u2013374.","journal-title":"Atherosclerosis"},{"key":"BFhr200966_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/01.ATV.0000252126.48375.d5","volume":"27","author":"K Inoue","year":"2007","unstructured":"Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T . Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161\u2013167.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFhr200966_CR21","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.amjcard.2005.07.042","volume":"96","author":"JY Kim","year":"2005","unstructured":"Kim JY, Ko YG, Shim CY, Park S, Hwang KC, Choi D, Jang Y, Chung N, Shim WH, Cho SY . Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005; 96: 1384\u20131388.","journal-title":"Am J Cardiol"},{"key":"BFhr200966_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cca.2008.06.021","volume":"396","author":"JJ Li","year":"2008","unstructured":"Li JJ, Qin XW, Yang XC, Li ZC, Zeng HS, Xu B, Gao Z, Wu YJ, Zhang X, Zhang CY . Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions. Clin Chim Acta 2008; 396: 38\u201342.","journal-title":"Clin Chim Acta"},{"key":"BFhr200966_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2169\/internalmedicine.47.0315","volume":"47","author":"H Sako","year":"2008","unstructured":"Sako H, Miura S, Iwata A, Nishikawa H, Kawamura A, Matsuo K, Shirai K, Saku K . Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina. Intern Med 2008; 47: 7\u201313.","journal-title":"Intern Med"},{"key":"BFhr200966_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1540-8183.2009.00429.x","volume":"22","author":"AG Rebeiz","year":"2009","unstructured":"Rebeiz AG, Zoghbi E, Harb R, Youhanna S, Skouri HN, Dimassi A, Abou-Nader G, Nasrallah A, Sawaya J, Gharzuddine W, Alam S . Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents. J Interv Cardiol 2009; 22: 169\u2013174.","journal-title":"J Interv Cardiol"},{"key":"BFhr200966_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00044011-200626040-00002","volume":"26","author":"HR Brunner","year":"2006","unstructured":"Brunner HR, Arakawa K . Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006; 26: 185\u2013193.","journal-title":"Clin Drug Investig"},{"key":"BFhr200966_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","volume":"36","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J . Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646\u2013661.","journal-title":"Am J Kidney Dis"},{"key":"BFhr200966_CR27","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/S0149-2918(01)80099-0","volume":"23","author":"WJ Elliott","year":"2001","unstructured":"Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK . Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001; 23: 1166\u20131179.","journal-title":"Clin Ther"},{"key":"BFhr200966_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1124\/jpet.106.112755","volume":"320","author":"T Iwanaga","year":"2007","unstructured":"Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I . Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211\u2013217.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFhr200966_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1291\/hypres.27.457","volume":"27","author":"G Derosa","year":"2004","unstructured":"Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R . Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457\u2013464.","journal-title":"Hypertens Res"},{"key":"BFhr200966_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/147323000102900402","volume":"29","author":"M Hanefeld","year":"2001","unstructured":"Hanefeld M, Abletshauser C . Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001; 29: 270\u2013279.","journal-title":"J Int Med Res"},{"key":"BFhr200966_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0021-9150(99)00145-8","volume":"146","author":"S Keidar","year":"1999","unstructured":"Keidar S, Attias J, Heinrich R, Coleman R, Aviram M . Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis 1999; 146: 249\u2013257.","journal-title":"Atherosclerosis"},{"key":"BFhr200966_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0021-9150(01)00714-6","volume":"162","author":"JE Figueroa","year":"2002","unstructured":"Figueroa JE, Vijayagopal P . Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis 2002; 162: 261\u2013268.","journal-title":"Atherosclerosis"},{"key":"BFhr200966_CR33","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","volume":"109","author":"M Schupp","year":"2004","unstructured":"Schupp M, Janke J, Clasen R, Unger T, Kintscher U . Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054\u20132057.","journal-title":"Circulation"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr200966.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr200966","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr200966.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:55:51Z","timestamp":1739120151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr200966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,22]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["BFhr200966"],"URL":"https:\/\/doi.org\/10.1038\/hr.2009.66","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"type":"print","value":"0916-9636"},{"type":"electronic","value":"1348-4214"}],"subject":[],"published":{"date-parts":[[2009,5,22]]}}}